Category: neuroendocrine cancer
Carcinoid NETs Health Storylines App Launches New Features
Living with Neuroendocrine Tumors (NETs) and Carcinoid Syndrome is not easy but two new features on the Carcinoid NETs Health Storylines App aim to make it a little easier.
Zebra Tales presents real stories about real life experiences by people…
READ MORE
October Luncheon with the Experts in White Plains, NY for the Neuroendocrine Tumor Community
The Big Apple NETs support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and 3 medical experts for Lunch with the Experts on Sunday, October 14, 2018 at 12:30 pm at the Westchester Hills Golf Club, 401 Ridgeway …
READ MORE
Peptide Receptor Radionuclide Therapy, PRRT: Updates and Locations
Since we shared the news of the FDA’s January 26, 2018 approval of peptide receptor radionuclide therapy, PRRT, with Lutathera (lutetium Lu 177 dotatate), more information has become available for the neuroendocrine tumor community, including updates…
READ MORE
Live Online Carcinoid Syndrome Program for Patients and Caregivers
Laugh and Learn with Comedian Steve Mazan
Come and laugh with Steve Mazan, stand-up comedian, inspirational speaker, and 13-year NET cancer survivor. “CS Happens” is a Laugh and Learn special evening for the NET community, and is complementary courtesy of Lexicon Pharmaceuticals. This unique…
READ MORE
Endocrinology Society Recognizes Neuroendocrine Cancer Physician and Researcher for Excellence at 2018 Annual Meeting
When Amit Tirosh, MD came to the United States in 2015 to be a senior endocrinologist at the National Institutes of Health (NIH), he began a journey that will lead full circle when he returns to Israel this summer to establish and lead a new neuroendocrine…
READ MORE
PRRT – FDA Approves Lutathera®, What’s Next?
The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community. It has also raised a host of questions including:
- What exactly is this
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors …
READ MORE
News about Neuroendocrine Cancer Expert Physicians
Three appointments and a newly established one-year neuroendocrine tumor (NET) fellowship herald an exciting new year for several NET specialists.
Edward M. Wolin, MD, Co-Medical Director of the Carcinoid Cancer Foundation, has been named Director…
READ MORE
NET Community Bicycle Raffle Recipients
In conjunction with Worldwide NET Cancer Awareness Day, November 10, the Carcinoid Cancer Foundation and Advanced Accelerator Applications are very excited to announce recipients of the recent Bicycle Giveaway Raffle.
Stefano Buono, CEO of Advanced…
READ MORE
